Loading...
•
Mar 31, 2021
Geron Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021, alongside company highlights and upcoming events.
Key Takeaways
Geron Corporation reported a net loss of $27.8 million, or $0.09 per share, for the first quarter of 2021. As of March 31, 2021, the Company had $244.7 million in cash and marketable securities, expected to fund operations until the end of 2022.
IMerge Phase 3 clinical trial in Myelodysplastic Syndromes is 75% enrolled and on track to complete enrollment in the second half of 2021.
Two abstracts accepted by the European Hematology Association for the 2021 Virtual Congress.
The first patient was dosed in IMpactMF, the Phase 3 clinical trial in MF.
Geron plans to become a commercial company in 2023 with the potential launch of imetelstat in lower risk MDS.
Geron
Geron
Forward Guidance
Geron continues to expect its operating expense burn to range from $108 to $112 million for fiscal year 2021 and plans to grow to approximately 80 to 85 employees by year-end 2021.